Affiliation: University of Oxford

Dr. Quin Xie is a postdoctoral fellow in the Nuffield Department of Clinical Neurosciences at the University of Oxford. Her PhD research investigated how environmental and microbial exposures shape immune development and metabolic health trajectories in children, with a particular focus on the role of the gut microbiota in the risk of type 1 and type 2 diabetes. Her doctoral work examined the interplay between the gut microbiota, immune responses, and therapeutic outcomes in youth-onset diabetes. She developed innovative approaches to identify immune-microbe interactions that predict response to teplizumab, the first FDA-approved immunotherapy for delaying the onset of type 1 diabetes.

In addition, Dr. Xie's research in adolescent obesity demonstrated that altered gut microbial biomass and systemic inflammation are associated with early metabolic dysfunction. She currently leads a study investigating brain changes associated with obesity and metabolic dysfunction using large-scale human datasets, complemented by in vivo and in vitro validation in multiple model systems.